Sign In
Buy LFCR
$4.42
+0.0600 (+1.38%)
At Close: Jul 31, 2026
Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 26'th Mar 2026
CHASKA, Minn., March 26, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated injectables contract development and manufacturing organization (“CDMO�
Lifecore Biomedical Signs Two New Agreements with Existing U.S. Biopharmaceutical Customer
07:00am, Thursday, 26'th Mar 2026
-- Site Transfer Agreement for the Manufacture of Commercially Marketed Product -- -- Second Agreement Supports the Expansion of Product Commercially Manufactured at Lifecore to a New Delivery System
Lifecore Biomedical Signs Commercial Site Transfer Agreement with Leading Medical Aesthetics Company
07:00am, Monday, 23'rd Mar 2026
-- Agreement for the Commercial Manufacture of Established, Approved Aesthetic Product -- -- Third Commercial Site Transfer Agreement Win in Five Months -- -- Program Expected to Generate Commercial R
SAN DIEGO, March 16, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Lifecore Biomedical, Inc. The investigation focuses on Lifecore Biomedica
Lifecore Biomedical, Inc. (LFCR) Q4 2025 Earnings Call Transcript
04:52pm, Monday, 16'th Mar 2026
Lifecore Biomedical, Inc. (LFCR) Q4 2025 Earnings Call Transcript
-- Recorded Fourth Quarter Revenues of $35.7 Million and Transition Period Revenues of $75.5 Million -- -- Multiple New Programs Signed in Fourth Quarter 2025 Including Two Commercial Site Transfer
Lifecore Biomedical to Participate in 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum
04:05pm, Tuesday, 10'th Mar 2026
CHASKA, Minn., March 10, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CD
CHASKA, Minn., March 09, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDM
Lifecore Biomedical Signs New Agreement with Indomo to Support Innovative Drug/Device Combination Acne Treatment
04:03pm, Wednesday, 04'th Mar 2026
Indomo Developing Fast-Acting, At-Home Treatment for Inflammatory Acne Lesions to be Administered with the ClearPen ™ , its Proprietary Intradermal Self-Injection Device Lifecore to Manufacture Drug
Lifecore Biomedical to Participate at DCAT Week 2026
07:05am, Tuesday, 17'th Feb 2026
CHASKA, Minn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO
Grabar Law Office is investigating claims on behalf of shareholders of Lifecore Biomedical, Inc. (NASDAQ: LFCR) as a securities fraud class action settles.
HALPER SADEH LLC ENCOURAGES LIFECORE BIOMEDICAL, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
05:09pm, Thursday, 29'th Jan 2026
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is inves
PHILADELPHIA, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Ibotta, Inc. (NYSE: IBTA): WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of Ibotta, Inc. (NYSE: IBTA).
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:45pm, Friday, 16'th Jan 2026
CHASKA, Minn., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today an
Halper Sadeh LLC Encourages Lifecore Biomedical, Inc. Shareholders to Contact the Firm to Discuss Their Rights
10:39am, Thursday, 15'th Jan 2026
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Lifecore Biomedical, Inc. (NASDAQ: LFCR) breached their fiduciary d
